Lineage Cell Therapeutics Stock Price and Value Analysis
Should you buy Lineage Cell Therapeutics stock? (NYSE American:BTX). Let's see how it does in our automated value investing analysis system.
BTX Free Cash Flow Trend
Hmm, we can't give any reliable projection for Lineage Cell Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
Inside the BTX Numbers
| BTX Price (Lineage Cell Therapeutics stock price per share) |
$8.52 | |
| [?]
|
PE Ratio versus Sector | 13% higher than other Healthcare stocks |
| [?]
|
PE Ratio versus Industry | 60% lower than other Biotechnology stocks |
| [?]
|
Cash Yield | -2.26% |
| [?]
|
Free Cash Flow Jitter | 11% |
Recent Insider Activity
Open-market buys and sells reported by Lineage Cell Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-12T00:00:00 | Culley Brian M (President and CEO) | Buy | 15,000 | $1.62 |
| 2025-01-27T00:00:00 | BROADWOOD PARTNERS, L.P. | Buy | 7,894,737 | $0.76 |
| 2025-01-27T00:00:00 | BROADWOOD PARTNERS, L.P. | Buy | 0 | -- |
| 2024-11-26T00:00:00 | Howe Jill Ann (Chief Financial Officer) | Buy | 15,000 | $0.59 |
| 2024-11-26T00:00:00 | Samuel George A. III (General Counsel) | Buy | 15,000 | $0.60 |
| 2024-11-22T00:00:00 | Mulroy Michael H. | Buy | 40,000 | $0.57 |
| 2024-11-21T00:00:00 | Culley Brian M (President and CEO) | Buy | 40,000 | $0.60 |
| 2024-08-16T00:00:00 | Howe Jill Ann (Chief Financial Officer) | Buy | 10,500 | $0.89 |
| 2024-05-24T00:00:00 | Culley Brian M (President and CEO) | Buy | 10,000 | $1.05 |
| 2024-02-08T00:00:00 | BAILEY DON M | Buy | 96,155 | $1.04 |
Is Lineage Cell Therapeutics Stock on Sale?
Based on our analysis, we believe that you should not buy Lineage Cell Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Should You Buy BTX Stock?
Does Lineage Cell Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.